Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation

Sung-Eun Lee, Ji-Young Lim, Tae Woo Kim, Da-Bin Ryu, Sung Soo Park, Young-Woo Jeon, Jae-Ho Yoon, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee and Chang-Ki Min

Abstract

Background: The aim of this study is to evaluate the prognostic impact of myeloid-derived suppressor cells (MDSCs) in multiple myeloma (MM) in the context of autologous stem cell transplantation (ASCT).

Methods: Peripheral blood samples were collected for measuring monocytic (M-) MDSCs (CD14 pos/HLA-DR low/neg) and early-stage (E-) MDSCs (Lin neg/HLA-DR neg/CD33 pos/CD11b pos) before and after ASCT. Clinical outcomes following ASCT differed according to the frequency of each MDSC phenotype.

Results: In the pre-ASCT analyses, lower M-MDSCs (<median) but not E-MDSCs were associated with a longer time to progression (TTP), whereas both MDSC phenotypes post-ASCT did not have a role in TTP. Both MDSC phenotypes pre-ASCT but not post-ASCT similarly suppressed in vitro autologous T and natural killer T cell proliferation. Importantly, pre-ASCT M-MDSCs more strongly inhibited the in vitro cytotoxic effect of melphalan compared with pre-ASCT E-MDSCs. Transcriptome analysis of each isolated MDSC subtype showed that expression of osteoclastic differentiation factors, particularly colony-stimulating factor 1 receptor (CSF1R), was significantly increased in M-MDSCs pre-ASCT. Finally, blockade of CSF1R substantially recovered the melphalan-induced cytotoxicity reduced by pre-ASCT M-MDSCs.

Conclusions: Our data demonstrate that pre-ASCT M-MDSCs are correlated with poor clinical outcomes after ASCT through reduced cytotoxicity of melphalan. We propose that targeting CSF1R on these cells may improve the results of ASCT in MM.

Keywords: Myeloid-derived suppressor cells, Colony-stimulating factor 1 receptor, Multiple myeloma, Autologous stem cell transplantation

Introduction

For over two decades, autologous stem cell transplantation (ASCT) has been the standard consolidation treatment for transplant-eligible patients with newly diagnosed multiple myeloma (MM) to improve depth of response, progression-free survival (PFS), and likely overall survival (OS) [1]. Currently, MM represents the most common indication for ASCT as the front-line or delayed settings [2, 3]. Use of the immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor bortezomib before and after ASCT improves clinical outcomes [4, 5], although the relative impact of choice of pre-transplant induction and post-transplant therapy on long-term survival remains unknown [6]. Despite these clinical improvements, the vast majority of patients eventually experience disease relapse and progression.

Large numbers of myeloid-derived suppressor cells (MDSCs), a mixture of monocytic and granulocytic cells, accumulate during many pathologic conditions, including cancer, infectious diseases, trauma, and sepsis. MDSCs are...
characterized by myeloid origin, immature state, and most importantly by their potent ability to suppress different aspects of immune responses, especially T cell proliferation and cytokine production [7]. Currently, using specific markers, MDSCs can be phenotypically characterized. In humans, granulocytic MDSCs (G-MDSCs) are defined as lacking expression of CD14 but expressing CD15/CD33/CD11b, whereas monocytes-MDSCs (M-MDSCs) express CD14/CD11b and are characterized as HLA-DR<sup>−</sup>/low cells or CD33<sup>+</sup> cells [8]. Lin<sup>−</sup> (including CD3, CD14, CD15, CD19, CD56) HLA-DR<sup>−</sup>CD33<sup>+</sup> cells contain mixed groups of MDSC comprising more immature progenitors, which have been defined as early-stage MDSC (E-MDSCs) [9]. MDSCs not only inhibit anti-tumour immunity, but also directly stimulate tumorigenesis, tumour growth, and tumour expansion [10].

A growing body of evidence suggests that MDSCs offer an appealing target for therapeutic intervention in cancer treatment [11, 12]. Down-regulation of MDSC frequencies and/or abrogation of their immunosuppressive functions have been reported to delay tumour growth and prolong survival in both animal models and cancer patients [13, 14]. The emerging role of MDSCs in MM pathogenesis and clinical behaviour has been highlighted, and their increase in both peripheral blood (PB) and bone marrow (BM) of MM patients with bidirectional interaction between MDSCs and malignant plasma cells within the MM microenvironment has been documented [15–17]. The presence of inflammatory cytokines after high-dose chemotherapy leads to proliferation and activation of MDSCs originating from autologous hematopoietic progenitors at the time of engraftment. Therefore, each subset of MDSCs before and/or after transplant could be considered as a prognostic predictor as well as an important target contributing to MM progression in the context to ASCT. Here, we investigate clinical correlations and preclinical proof-of-concept data on the role of MDSCs in transplant outcomes and highlight the mechanistically relevant protection of MM against melphalan and the host immune system.

Materials and methods

Patients and transplant procedures

A total of 100 consecutive patients with MM who underwent ASCT as part of a front-line treatment at our institution between January 2013 and December 2016 were enrolled in this analysis. General ASCT procedures are summarized in the supplemental data (Additional file 1) [18].

Blood sample collection and isolation of peripheral blood mononuclear cells (PBMCs)

Blood samples for the analysis of MDSC frequency were collected at diagnosis and pre- and post-ASCT. Pre-ASCT sampling was performed before conditioning chemotherapy, and post-ASCT sampling was done one day after neutrophil engraftment. PBMCs were freshly isolated from whole blood (30 mL) and were processed immediately for flow cytometric analysis.

Flow cytometric analysis and isolation of MDSCs from PBMCs

MDSCs were phenotypically divided into two categories, M-MDSCs and E-MDSCs. E-MDSCs immunophenotyped as the HLA-DR<sup>−</sup>Lin<sup>−</sup>CD11b<sup>+</sup>CD33<sup>+</sup> population and M-MDSCs as the HLA-DR<sup>−</sup>CD14<sup>+</sup> population were quantitated as a percentage of PBMCs (Additional file 4: Figure S1). Monoclonal antibodies for the identification of E- and M-MDSCs and isolation of MDSCs from PBMCs are summarized in the supplemental data (Additional file 1).

Quantitative reverse transcription (qRT)-PCR analysis of MDSC RNAs

One microgram of total RNA was reverse transcribed into cDNA. Quantitative assessment of target mRNA levels was performed by real-time PCR with a CFX96 Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). Primer sequences were as previously described (Additional file 2: Table S1) [19].

T cell suppression assay

MDSCs and T cells were isolated from PBMCs of MM patients. Isolated MDSCs were cocultured with CFSE-labelled autologous T cells (MDSC:T cell ratio 1:1). T cell stimulation was provided by 2 μg/ml of anti-CD3/CD28 (eBioscience, San Diego, CA, USA) and 5 ng/ml of recombinant human IL-2 (R&D Systems, Minneapolis, MN, USA). After five days of incubation, the cells were stained with anti-CD4, anti-CD8, and anti-CD56 (eBioscience). Proliferation of T cells was analysed using LSRII (BD Pharmingen, San Jose, CA, USA) and Flowjo software (Ashland, OR, USA).

Assay for apoptosis

CFSE-labelled IM-9, RPMI 8266, OPM2 cell lines and primary MM cells were cultured with or without isolated MDSCs (MM cell:MDSC ratio 1:1) in the presence of human M-CSF. The cocultured CFSE-positive cells were then incubated with or without 10 μM melphalan and 500 nM BLZ945 (Additional file 1). After incubation for 48 h, the cells were harvested, stained with Annexin V-APC and propidium iodide (PI), and examined by flow cytometry. Data obtained from flow cytometry were analysed using Flowjo software.

Transcriptome sequencing and bioinformatics analysis

RNA extraction, cDNA library preparation, and bioinformatics analysis of the sequencing data are summarized in the supplemental data (Additional file 1).
Definitions and statistical analysis
OS from transplantation was defined as the time from ASCT to death from any cause, and surviving patients were censored at the last follow-up. PFS was measured as the time from ASCT to disease progression or death (regardless of cause), whichever came first. We wanted to observe the effect of circulating MDSCs on disease progression after ASCT. Therefore, time to progression (TTP) was calculated as time from ASCT to disease progression, with deaths due to causes other than progression censored. Statistical analyses are summarized in the supplemental data (Additional file 1).

Results
Patients and transplant outcomes
A total of 100 patients, 59 males and 41 females, with a median age of 56 years (range, 33–67 years) were analysed in this study (Additional file 3: Table S2). Median disease duration before ASCT was 7.0 months (range, 2.9–12.3 months). The International Staging System (ISS) stages II, II, and III at diagnosis comprised 29, 44, and 23% of subjects, respectively, with 4% unknown ISS [20]. After induction chemotherapy, 43 (43%), 35 (35%), and 22 (22%) patients had complete response, very good partial response (VGPR), and PR, respectively. The median OS and PFS were 84.8 ± 4.6% and 42.2 ± 6.3%, respectively, and the 3-year TTP was 43.8 ± 6.3% (median TTP was 26.6 months).

Changes in MDSCs during induction chemotherapy and ASCT
Figure 1a shows serial changes in MDSC phenotypes through induction chemotherapy and ASCT. At diagnosis, absolute number of E-MDSC phenotype was 0.9 ± 0.2 × 10⁶/L, which significantly increased to 2.4 ± 0.3 × 10⁶/L (P = 0.002) after induction chemotherapy. In contrast, absolute number of M-MDSC phenotype was significantly decreased after induction chemotherapy, from 31.6 ± 6.0 × 10⁶/L at diagnosis to 21.3 ± 4.6 × 10⁶/L (P < 0.001). When absolute numbers of pre-and post-ASCT MDSC phenotypes were compared, there was no difference in E-MDSC phenotypes (P = 0.757), whereas M-MDSC phenotype increased after ASCT (P < 0.001). The frequency of E-MDSC phenotypes at time of diagnosis was not significantly different among the three groups divided by the ISS, whereas a higher frequency of M-MDSCs was significantly associated with a higher ISS stage (Additional file 5: Figure S2).

Expansion of MDSCs in relation to time to progression (TTP)
Next, we evaluated how each MDSC phenotype in both pre- and post-ASCT correlated with the 3-year TTP. The patients were grouped according to median frequency value of each MDSC phenotype. First, the association of pre-ASCT MDSCs with the 3-year TTP was analysed and showed that there was no difference between the high and low E-MDSCs groups (52.2% vs. 32.3%, P = 0.352) (Fig. 1b, top left). In contrast to the E-MDSCs groups, the 3-year TTP was significantly lower in the high M-MDSC group compared with the low M-MDSC group (34.3 vs. 52.9, P = 0.049, Fig. 1b top right). Second, we also analysed the effect of post-ASCT MDSCs on the 3-year TTP, which showed that neither E- or M-MDSC phenotype correlated with the 3-year TTP (Fig. 1b, bottom). Ultimately, after adjusting for potential risk factors (immunoglobulin type and serum calcium level at diagnosis), multivariate analysis revealed that the high M-MDSC group pre-ASCT was associated with a lower TTP, with an HR of 0.49 (95% CI, 0.24 to 0.99, P = 0.045) (Table 1).

Functional characterization of pre- and post-ASCT MDSCs
To investigate the functional characterization of each MDSC phenotype in both pre- and post-ASCT, we isolated E- and M-MDSC phenotypes from patients’ PBMCs collected pre- and post-ASCT. And then, we tested autologous T- and NKT-cell suppression mediated by each MDSC phenotype (Fig. 2). Both pre-ASCT E- and M-MDSC phenotypes had similarly suppressed autologous T- and NKT-cell proliferation. In contrast, E- and M-MDSC phenotypes post-ASCT did not show suppressive effects on autologous T- and NKT-cells, which indicates these cells are not MDSCs but rather monocytes. It has been shown that MM-associated macrophages protect MM cells from chemotherapy drug-induced apoptosis in vitro [21]. M2-polarized macrophages also mainly upregulate CD200R and CD206 and downregulate CD14 [22]. CD200R and CD14 were expressed in M2 macrophages but not in pre-transplant isolated MDSC phenotypes (Additional file 6: Figure S3).

Role of each MDSC phenotype in melphalan-induced cytotoxic activity
To better understand the mechanisms leading to poor prognosis mediated by the pre-ASCT, but not post-ASCT, M-MDSC phenotype, we tested the influence of E- and M-MDSCs isolated from patient PBMCs on in vitro melphalan-induced cytotoxic assay according to time before and after ASCT. First, in the test using the MM cell line (IM-9) (Fig. 3a), pre-ASCT M-MDSCs inhibited melphalan-induced cytotoxic effects more strongly than pre-ASCT E-MDSCs. In contrast, isolated
cells of M- and E-MDSC phenotype post-ASCT did not have any inhibitory effect on melphalan-induced cytotoxic activity. Next, primary CD138+ cells taken from patients’ BM were examined for melphalan-induced cytotoxicity in the presence of E- and M-MDSCs isolated from another patient at the time before and after ASCT (Fig. 3b). Similarly, pre-ASCT M-MDSCs were capable of reducing the cytotoxic activity of melphalan on primary myeloma cells more strongly than pre-ASCT E-MDSCs, whereas the post-ASCT MDSC phenotypes did not show the inhibitory effect.

**Differentially expressed genes between E-MDSC and M-MDSC phenotypes before and after ASCT**

As we found a negative impact of pre-ASCT M-MDSCs on TTP and in vitro melphalan-induced cytotoxicity, we were interested in which genes were differentially expressed between pre-ASCT E- and M-MDSCs. Using
transcriptome resequencing, we analysed KEGG pathways for 533 differentially expressed genes between E- and M-MDSC populations using a threshold of a 2-fold change and P-value <0.05. We found that the most remarkable difference was osteoclast differentiation in pre-ASCT M-MDSCs versus E-MDSCs (Fig. 4a). In contrast, no difference in expression of osteoclast differentiation was observed between post-ASCT E- and M-MDSC phenotypes (Fig. 4b). Next, we investigated the differentially expressed genes associated with osteoclast differentiation. Among them, CSF1R was a highly expressed gene in pre-ASCT M-MDSCs compared to other phenotypes of MDSCs (Fig. 4c). These results were confirmed using qRT-PCR in isolated peri-ASCT E- and M-MDSC phenotypes. mRNA expression of CSF1R was much higher in pre-ASCT M-MDSCs (n = 9) than pre-ASCT E-MDSCs (n = 8) (P < 0.001; Fig. 4d, left), whereas there was no difference between post-ASCT M- (n = 11) and E-MDSC phenotypes (n = 12) (Fig. 4d, right).

Relationships between serum levels of CSF1R ligands and circulating MDSC frequencies

Next, we measured factors such as M-CSF and IL-34, which are known to trigger CSF1R signalling in patient sera (n = 75 for M-CSF, n = 82 for IL-34) [23]. In correlation analysis between these factors and the frequency of pre-ASCT MDSCs, M-CSF was correlated with M-MDSCs frequency (R^2 = 0.1049, P = 0.005), verifying that M-CSF enhanced M-MDSCs proliferation (Fig. 4e, top left), but IL-34 did not correlate with M-MDSCs (Fig. 4e, top right). On the other hand, there was no relationship between these factors and the frequency of pre-ASCT E-MDSCs (Fig. 4e, bottom). Furthermore, neither post-ASCT E- (Fig. 4f, top) nor M-MDSC phenotype (Fig. 4f, bottom) was related to level of M-CSF or IL-34.

CSF1R signalling is critical for attenuation of melphalan-induced cytotoxic effect by pre-ASCT M-MDSCs

Finally, to determine whether a CSF1R inhibitor can recover melphalan-induced cytotoxicity attenuated by pre-ASCT M-MDSCs, we examined the influence of BLZ945, a human CSF1R inhibitor, on cell death induced by melphalan (Fig. 5a). Presence of CSF1R inhibitor reversed the protective effect of pre-ASCT M-MDSCs on IM-9 cells. However, BLZ945-treated pre-ASCT E-MDSCs did not affect survival of the MM cells. The effect of post-ASCT E- and M-MDSC phenotypes on melphalan-induced cytotoxicity was not affected by BLZ945 treatment. Similar results were obtained using the RPMI 8226 and OPM2 cell lines (Additional file7: Figure S4). Taken together, these results demonstrate that inhibition of CSF1R signalling results in recovery of anti-MM activity by melphalan, which is attenuated by pre-ASCT M-MDSCs. In addition, we measured several cytokines in the culture supernatants and compared them according to BLZ945 treatment because cytokines are major proliferative factors for malignant plasma cells. Although the concentrations of IL-6, IGF1, and VEGF with pre-ASCT M-MDSCs were higher than those with pre-ASCT E-MDSCs, BLZ945 treatment did not have an effect on their concentrations in the presence of pre-ASCT M-MDSC phenotypes (Fig. 5b, bottom). Concentrations of those cytokines in culture supernatants were not changed in the presence of post-ASCT MDSC phenotypes (Fig. 5b, bottom). Importantly, only M-CSF concentration was significantly decreased in the culture supernatants with pre-ASCT M-MDSCs after BLZ945 treatment (Fig. 5c).

Discussion

The objective of this study is not only to provide a comprehensive analysis of MDSC biology in patients with MM undergoing ASCT, but also to suggest molecular

### Table 1 Predictive factors for time to progression

| Univariate analysis | RR (95% CI) | P     |
|---------------------|-------------|-------|
| Age at diagnosis (years), continuous | 1.00 (0.96−1.04) | 0.855 |
| Sex (F vs. M) | 0.92 (0.50−1.71) | 0.802 |
| Durie-Salmon stage at diagnosis (III vs. II) | 1.29 (0.54−3.08) | 0.567 |
| ISS stage at diagnosis (III vs. I-II) | 0.64 (0.29−1.39) | 0.257 |
| Cytogentic (high risk vs. standard) | 1.81 (0.80−4.08) | 0.155 |
| Immunoglobulin type (others vs. light chain only) | 2.27 (1.04−4.93) | 0.039 |
| Myeloma bone disease on plain radiographs (no vs. yes) | 1.69 (0.89−3.919) | 0.107 |
| Cr at diagnosis (mg/dL), (2.2 vs. < 2) | 0.61 (0.29−1.28) | 0.189 |
| Hb at diagnosis (g/dL), (28.5 vs. < 8.5) | 0.58 (0.31−1.08) | 0.084 |
| Ca at diagnosis (mg/dL), (≥10 vs. < 10) | 1.01 (0.49−2.07) | 0.985 |
| B2-microglobulin at diagnosis (mg/dl), (2.55 vs. < 5.5) | 0.60 (0.28−1.31) | 0.199 |
| Albumin at diagnosis (mg/dl), (2.35 vs. < 3.5) | 0.58 (0.31−1.08) | 0.083 |
| LDH at diagnosis (U/L), (2450 vs. < 450) | 1.20 (0.60−2.43) | 0.607 |

| Multivariate analysis | RR (95% CI) | P     |
|-----------------------|-------------|-------|
| Immunoglobulin type (others vs. light chain only) | 2.01 (0.77−5.24) | 0.153 |
| Hb at diagnosis (g/dL), (28.5 vs. < 8.5) | 0.79 (0.40−1.58) | 0.507 |
| Albumin at diagnosis (mg/dl), (2.35 vs. < 3.5) | 0.60 (0.30−1.020) | 0.148 |
| Pre-ASCT M-MDSC frequency (Low vs. high) | 0.49 (0.24−0.99) | 0.045 |

Cr Calcium, Cr Creatinine, CI Confidence interval, F Female, Hb Hemoglobin, LCD Light chain disease, LDH Lactate dehydrogenase, M Male, TTP Time to progression
and functional mechanisms for the effects of MDSCs on transplant outcomes. MDSCs have emerged as major regulators in diseases that involve chronic inflammation, especially cancer, but also infection, autoimmune diseases, trauma, graft-versus-host disease, and others. Although evidence of the clinical significance of MDSCs in cancer has emerged, previous studies have several limitations in that phenotypic characterization for human MDSCs is heterogeneous, and functional analyses of immunoregulatory activity are often lacking for practical reasons, mainly related to the paucity of MDSCs in human samples [9]. With recent studies, the cellular nature of human MDSCs has been better defined as G-MDSCs, M-MDSCs, and E-MDSCs [9, 24]. However, due to lack of unique phenotypic markers, suppressive activity is still important to characterize MDSCs from other cells referred to as tumour-associated neutrophils or monocytes [25, 26]. In this study, we showed for the first time that two main subgroups of MDSCs, E- and M-MDSCs, differentially affected clinical outcomes following ASCT. In the pre-ASCT analyses, higher M-MDSCs but not E-MDSCs were associated with a lower TTP, whereas neither MDSC phenotype post-ASCT had a role in TTP. Both MDSC subtypes pre-ASCT but not post-ASCT similarly suppressed in vitro autologous T and natural killer T cell proliferation. Therefore, according to established definition [9], phenotypic post-ASCT M-MDSCs and E-MDSCs are not MDSCs but rather monocytes and progenitors, respectively. Importantly, pre-ASCT E-MDSCs more potently inhibited in vitro cytotoxic effects of melphalan compared with pre-ASCT E-MDSCs. Until now, although the important attribute of immune-suppressive activity of MDSCs is known well, the potential targets on these cells responsible for poor clinical outcomes after ASCT remain to be fully characterized. By more sophisticated biochemical and transcriptome analysis of each isolated MDSC subtype, we showed that expression of osteoclastic differentiation

![Figure 2](https://jitc.bmj.com/content/7/1/35/F2.large.jpg)

**Fig. 2** Suppressive function of pre- and post-ASCT MDSC phenotypes. We isolated E- and M-MDSC phenotypes from six patients’ PBMCs collected pre- and post-ASCT and tested autologous CD4, CD8 T-, and NKT-cell suppression mediated by each MDSC phenotype. The top figures are representative and individual data from independent experiments using MDSC phenotypes isolated from the six patients, as shown in the bottom figure. Both pre-ASCT E- and M-MDSC subsets had similarly suppressed autologous CD4 (left), CD8 T- (middle), and NKT-cell (right) proliferation. In contrast, post-ASCT E- and M-MDSC phenotypes did not show suppressive effects on those immune cells. The data are presented as the mean ± SEM. **P < 0.01; ***P < 0.001
Fig. 3 (See legend on next page.)

A

|        | Pre-ASCT | Post-ASCT |
|--------|----------|-----------|
|        | Alone    | E-MDSCs   | M-MDSCs   |
| E-MDSCs| 0.217    | 1.21      | 0.335     |
| M-MDSCs| 0.416    | 0.843     | 0.537     |

Veh

Melphalan

B

|        | Pre-ASCT | Post-ASCT |
|--------|----------|-----------|
|        | Alone    | E-MDSCs   | M-MDSCs   |
| E-MDSCs| 4.456    | 1.12      | 0.537     |
| M-MDSCs| 27.1     | 1.34      | 1.25      |

Veh

Melphalan

---

**Fig. 3** (See legend on next page.)
The differential effect of MDSC subtypes on cancer cells

As suggested in our study, influence of circulating the overlapping PGE2/COX-2/STAT3 pathways [37, 40, G-MDSCs protected MM cells from chemotherapy [42].

In terms of the suppressive mechanisms of MDSCs in cancer patients, MDSCs have been found to employ a range of different cellular and molecular suppressive strategies. These mechanisms included Treg induction and activation of MDSCs in MM patients [32, 33]. Because the direct actions and functional consequences of MDSCs on MM cells, especially in the context of ASCT, are poorly defined, our results further extend the understanding of the role of MDSCs and development of therapeutic strategies to target MDSCs in patients with MM undergoing ASCT.

The correlation between the systemic expansion of MDSCs and clinical outcome has been reported for both solid and hematologic human malignancies, confirming that MDSCs can influence tumour growth and metastases [10, 27]. Previous studies have investigated the clinical relevance of MDSCs in terms of tumour burden and clinical stage [28], sensitivity to chemo- and immunotherapy [29], and association with patient survival [30] in various types of cancer. Tumor-promoting and immune-suppressive roles of MDSCs in the MM microenvironment are also emerging [31]. Görgün et al. reported that MDSCs are increased in patients with MM and have bidirectional interaction with tumours within the MM microenvironment [15]. MDSCs from MM patients promote MM tumour growth and induce immune suppression; conversely, MM cells induce MDSC development. Other studies have also reported the presence and activation of MDSCs in MM patients [32, 33].

In terms of the suppressive mechanisms of MDSCs in cancer patients, MDSCs have been found to employ a range of different cellular and molecular suppressive strategies. These mechanisms included Treg induction [34], ROS [35, 36], arginase [15, 37], TGF-β [38, 39], and the overlapping PGE2/COX-2/STAT3 pathways [37, 40, 41]. As suggested in our study, influence of circulating M-MDSCs on clinical outcomes has been commonly reported in cancer patients. On the other hand, some studies have reported significantly higher level of G-MDSCs in cancer patients compared with healthy individuals, and Ramachandran et al. demonstrated that G-MDSCs protected MM cells from chemotherapy [42]. The differential effect of MDSC subtypes on cancer cells should be interpreted cautiously because of the possibility of ambiguity in definition of MDSC subtypes across previously reported studies. In our current study, both MDSC phenotypes pre-ASCT but not post-ASCT had similarly suppressed in vitro autologous T and natural killer T cell proliferation. These results suggest that pre-ASCT M-MDSCs have a similar nature to those previously reported in cancer patients, whereas their characteristics were different from post-ASCT MDSC phenotypes, which were expanded from autologous peripheral blood progenitors as a secondary inflammatory response. In our previous study, both MDSC subtypes isolated early after allogeneic SCT had a capacity to suppress T cell proliferation, suggesting that alloimmune response greatly contributes to the immunosuppressive effect of MDSCs [19].

Despite the advent of novel agents and doubling of survival rates, MM is still considered an incurable malignancy [43], and ASCT is still the first-line treatment for transplant eligible patients [44]. MM is characterized by generalized immune suppression that contributes to susceptibility to infection, as well as tumour progression [45] and bidirectional interaction between malignant plasma cells and the BM microenvironment, which has a substantial role in chemotherapy resistance and thereby the persistence of residual disease [46, 47]. Therefore, to improve the efficiency of ASCT, we highlight MDSCs as an important target for therapeutics for patients with MM. Interestingly, we found that blockade of CSF1R recovered melphalan-induced cytotoxicity reduced by pre-ASCT M-MDSCs, which suggests that targeting CSF1R on M-MDSCs pre-ASCT may improve the results of ASCT in MM. Strategies for overcoming MDSC-mediated immune suppression have so far focused on reducing their level, inhibiting their suppressive function, or influencing their differentiation. Ramachandran et al. showed that growth of immunogenic MM cells was significantly reduced in S100A9KO mice, which are deficient in their ability to accumulate MDSCs in tumour-bearing hosts [17]. However, whether MDSC-mediated suppression in MM can be abrogated using inhibition of the possible suppressive pathway remains to be studied. Recently, Wang et al. explored the potential of targeting myeloma-associated macrophages

(See figure on previous page.)

**Fig. 3** The influence of pre- and post-ASCT MDSC phenotypes on in vitro melphalan-induced cytotoxic assay. MM cell line, IM-9 cells (a) or primary MM cells (b) were cultured with or without MDSCs isolated from pre- and post-ASCT samples (MM cell/MDSC ratio 1:1) in the presence of human M-CSF. The top figures are representative staining with Annexin V-APC and PI after incubation with or without melphalan. In the bottom figure, individual data from independent melphalan-induced cytotoxic assay by E- and M-MDSC phenotypes isolated from five patients were compared. The label of post-ASCT MDSCs on the figure means the cells expressing each MDSC phenotype. The data are presented as the mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
Fig. 4 Transcriptome profiling analysis of isolated E- and M-MDSC phenotypes. The top 20 KEGG pathways for 533 differentially expressed genes between pre-ASCT E- and M-MDSC populations (a) and for 65 differentially expressed genes between post-ASCT E- and M-MDSC phenotypic populations (b), using a threshold of a 2-fold change and P-value < 0.05. The most remarkable difference was osteoclast differentiation in pre-ASCT M- versus E-MDSCs, which was not observed in post-ASCT M- versus E-MDSC phenotypes. Among the genes associated with osteoclast differentiation, CSF1R was the most significant (c) and was confirmed using qRT-PCR in isolated peri-ASCT E- and M-MDSC phenotypes (d). The data are presented as the mean ± SEM. * P < 0.05. Next, M-CSF and IL-34, which are known to trigger CSF-1R signalling in patient sera (n = 75 for M-CSF, n = 82 for IL-34), were measured, and the correlation between these factors and the frequency of pre-ASCT (e) and post-ASCT (f) MDSC phenotypes was analysed. The Spearman correlation coefficient was used to evaluate association for continuous variables. The label of post-ASCT MDSCs on the figure means the cells expressing each MDSC phenotype.
Fig. 5 (See legend on next page.)
using CSF1R-blocking mAb in mice suggesting that this approach may sensitize myeloma cells to chemotherapy and promote anti-myeloma immune responses. [48]. On the other hand, we focused on the effect of targeting human pre-ASCT M-MDSCs using the CSF1R blockade BLZ945. Our data are consistent with other studies showing that CSF1R blockade by inhibitors and antibodies improves therapeutic efficacy in various solid cancers [49, 50]. These findings support the possibility of repositioning of CSF1R blockade by inhibitors and antibodies into MM therapy in the context of ASCT. However, in this study, in vivo preclinical tests were not performed and characteristics of malignant plasma cells, such as cytogenetic abnormalities, were not considered. It is therefore unknown whether MDSC-targeted therapies will bring clinical benefit to patients. Further studies are needed to confirm the efficacy of CSF1R blockade by inhibitors and antibodies in patients with MM undergoing ASCT.

Conclusions
In summary, we demonstrated that pre-ASCT M-MDSCs correlate with poor clinical outcomes after ASCT through reduced melphalan efficacy and propose that targeting CSF1R on these cells may improve the ASCT outcomes in MM. Although it is not known whether targeting CSF1R shows selective suppression against M-MDSCs in vivo, this study shows a possible strategy for overcoming M-MDSC-mediated reduction of melphalan effect in MM patients undergoing ASCT. Future studies should attempt to prove efficacy and safety in clinics.

Additional files

Additional file 1: Supplementary Materials and Methods. (DOCX 24 kb)
Additional file 2: Table S1. Primers used for qPCR amplification. (DOCX 19 kb)
Additional file 3: Table S2. Baseline characteristics of patients. (DOCX 22 kb)
Additional file 4: Figure S1. Representative immunophenotypes of E- and M-MDSCs from PBMCs. Representative FACS plots of E- and M-MDSC phenotypes in PBMCs taken at the time of engraftment after ASCT. (TIF 180 kb)

Additional file 5: Figure S2. Correlation between the frequency of E- and M-MDSC phenotypes at diagnosis and disease stage by the International Staging System. The frequency of E- and M-MDSC phenotypes at diagnosis was compared in the three groups (\(n = 56, 93, 79\) for stage I, II, and III, respectively). The data are presented as the mean ± SEM. * \(P < 0.05\); ** \(P < 0.01\); *** \(P < 0.001\) (TIF 36 kb)

Additional file 6: Figure S3. Different macrophage gene expression between M2 polarized macrophages and pre-ASCT M-MDSCs. M2 macrophages, E- and M-MDSCs were isolated from PBMCs in pre-ASCT (\(n = 9\)). Expression of CD200R and CD206 was assessed in M2 macrophages and pre-transplant isolated MDSCs by qRT-PCR. (TIF 34 kb)

Additional file 7: Figure S4. The influence of CSF1R inhibition on melphalan-induced cytotoxicity attenuated by pre-ASCT M-MDSCs was assessed in the RPMI 8266 (a) and OPM2 cell lines (b). The same procedure as in Fig. 5 was carried out. (PDF 1259 kb)

Abbreviations
ASCT: Autologous stem cell transplantation; BM: Bone marrow; E-MDSCs: Early-stage MDSCs; G-MDSCs: Granulocytic MDSCs; ISS: International staging system; MDSCs: Myeloid-derived suppressor cells; MM: Multiple myeloma; M-MDSCs: Monocytic MDSCs; OS: Overall survival; PB: Peripheral blood; PBMCs: Peripheral blood mononuclear cells; PFS: Progression-free survival; qRT-PCR: Quantitative reverse transcription-PCR; TTP: Time to progression; VGPR: Very good partial response

Acknowledgements
Not applicable

Funding
This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI16C0047).

Availability of data and materials
All the data generated or analyzed during this study are included in this published article and its Additional files.

Authors’ contributions
C-KM had primary responsibility for study design, collection and assembly of data, data analysis and interpretation, and manuscript writing; S-EL and J-YL interpreted and analyzed data, performed statistical analysis and wrote the manuscript. J-YL, TWK, and D-BR performed laboratory work. SSP, Y-WJ, J-HY, B-SC, K-SE, Y-JK, H-JK, SL, S-GC, D-WK, and J-WL contributed to interpretation. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Written informed consent was obtained from each patient before participation in this study. This study was approved by the Institutional Review Board of The Catholic University of Korea.
Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 24 August 2018 Accepted: 20 December 2018
Published online: 07 February 2019

References
1. Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):v113–7.
2. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26.
3. Durie BG, Heering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed multiple myeloma without intent for immediate autologous stem-cell transplantation (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519–27.
4. Gay F, Jackson G, Rosolino L, Holstein SA, Moreau P, Spada S, et al. Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis. J Clin Oncol. 2017;35:3279–89.
5. Cornell RF, D’Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, et al. Myeloid-derived suppressor cells in the tumor microenvironment in humans. Blood. 2013;121:3367–71.
6. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow microenvironment: expect the unexpected. J Clin Invest. 2015;125:3356–67.
7. Youn JI, Gabrilovich DI. Myeloid cell-dependent tumor angiogenesis in mice: a genetic approach. J Virol. 2014;88:7678–82.
8. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.
9. Malek E, de Lima M, Letterio JJ, Kim BG, Finke JH, Driscoll JJ, et al. Myeloid-derived suppressor cells: the cells of the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125:3356–64.
10. Melani C, Sangaletti S, Barazzetta FM, Webb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 2007;67:11438–46.
11. Kujauskis M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid-cell-dependent tumor angiogenesis in mice. J Clin Invest. 2008;118:3367–77.
12. Filippazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother. 2012;61:255–64.
13. Filipazzi P, Vaigl T, et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol. 2013;190:3815–23.
14. Lee SE, Yoon JH, Shin SH, Cho BS, Eom KS, Kim YJ, et al. Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma. Ann Hematol. 2014;93:627–34.
15. Lee SE, Lim JY, Kim TW, Jeon YW, Yoon JH, Cho BS, et al. Matrix metalloproteinase-9 in Monocytic myeloid-derived suppressor cells correlate with early infections and clinical outcomes in allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24:32–42.
16. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Judge J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:2412–20.
17. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009;114:3625–8.
18. Ambarus CA, Krausz S, van Eijk M, Hamann J, Reddick RA, Weedon J, et al. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods. 2012;375:196–206.
19. Ichikawa J, Zlotnik A. Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage. J Leukoc Biol. 2016;100:481–9.
20. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111:4233–44.
21. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta. “N1” versus “N2” TAN. Cancer Cell. 2009;16:183–94.
22. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22:231–7.
23. Scioli S, Marigo I, Pinton P, Damuozza V, Manuzza V, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci. 2014;1319:47–65.
24. Jordan KR, Aramia RN, Ramirez O, Callihan EB, Gao D, Bosakove M, et al. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother. 2013;62:1711–22.
25. Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother. 2014;63:247–57.
26. Liu J, Zhou Y, Huang Q, Qiu L. CD14+(HLA-DRlow)/CD16+ monocytic cells associate with prognosis in patients with chronic myelogenous leukemia. J Hematol Oncol. 2010;3:21.
27. Malek E, de Lima M, Letterio JJ, Kim BG, Finke JH, Driscoll JJ, et al. Myeloid-derived suppressor cells: the cells of the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125:3356–64.
28. Wang Z, Zhang L, Wang H, Xiong S, Li Y, Tao Q, et al. Tumor-induced CD14+HLA-DR (+/−)flow myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients. Cancer Immunol Immunother. 2015;64:389–99.
29. Brimnes MK, Vangstad AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE, et al. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR(+)flow myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol. 2010;72:540–7.
30. Jtschin R, Braun M, Buttmann M, Dettmer-Wilde K, Bricks J, Berger J, et al. CLL-cells induce IDOxs CD14+HLA-DRlow myeloid-derived suppressor cells that inhibit T-cell responses and promote Tregs. Blood. 2014;124:750–60.
31. Schmiedlau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 2001;61:4756–60.
32. Mao Y, Sarhan D, Steven A, Seliger B, Kessling R, Lundqvist A. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res. 2014;20:4096–106.
33. Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J, et al. STAT3 regulates arginase-1 in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013;123:1580–9.
34. Filippazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma
patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25:2546–53.

39. Chikamatsu K, Sakakura K, Toyota M, Takahashi K, Yamamoto T, Masuyama K. Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck. Cancer Sci. 2012;103:976–83.

40. Mao Y, Poschke I, Wenneberg E, Pico de Coana Y, Egyhazy Brage S, Schultz L, et al. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res. 2013;73:3877–87.

41. Hossain DM, Pal SK, Moreira D, Duttagupta P, Zhang Q, Won H, et al. TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate Cancer patients. Clin Cancer Res. 2015;21:3771–82.

42. Ramachandran IR, Condamine T, Lin C, Herlihy SE, Garfall A, Vogl DT, et al. Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. Cancer Lett. 2016;371:117–24.

43. Mahendra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012;9:335–43.

44. Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011;118:5762–8 quiz 982.

45. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. 2007;138:563–79.

46. Kawano Y, Moschetta M, Manier S, Glaye S, Gorgun GT, Roccaro AM, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015;263:160–72.

47. Andrews SW, Kabrah S, May JE, Donaldson C, Morse HR. Multiple myeloma: the bone marrow microenvironment and its relation to treatment. Br J Biomed Sci. 2013;70:110–20.

48. Wang Q, Lu Y, Li R, Jiang Y, Zheng Y, Qian J, et al. Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma. Leukemia. 2018;32:176–83.

49. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19:1264–72.

50. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25:846–59.